Wegovy Tablets Vs Injections

If you have been struggling with your weight for years and feel like nothing has worked, you are not alone — and Wegovy tablets may be the clinically proven option you have been looking for. Approved by the MHRA for use in the UK, this semaglutide-based treatment has transformed how doctors approach obesity and weight management, offering real, measurable results for people who have already tried diet and exercise without lasting success.

Quick Summary

Wegovy is a once-weekly semaglutide injection that works by mimicking a natural hormone in your body to reduce appetite and promote significant, sustained weight loss. It is prescribed for adults with a BMI of 30 or above, or 27 and above with a weight-related health condition, and is backed by some of the most compelling clinical evidence in obesity medicine to date.

• Wegovy contains semaglutide 2.4mg and belongs to the GLP-1 receptor agonist class of medicines
• Clinical trials show an average body weight reduction of around 15% over 68 weeks
• It is administered once weekly as a subcutaneous injection, not an oral tablet
• Doses are escalated gradually over five months to reduce gastrointestinal side effects
• It is available in the UK through private prescription and select NHS pathways in 2026

Table of Contents

1. What Are Wegovy Tablets and How Do They Work?
2. Who Can Use Wegovy for Weight Loss in the UK?
3. Wegovy Dose Escalation: Understanding the Treatment Schedule
4. Common Side Effects of Wegovy and How to Manage Them
5. Wegovy Versus Other Weight Loss Treatments Available in the UK
6. How to Get Wegovy Safely Through a UK Online Pharmacy
7. Key Takeaways
8. When to Seek Professional Advice
9. Scientific References
10. Frequently Asked Questions

What Are Wegovy Tablets and How Do They Work?

Despite what many people search for online, Wegovy is not available in a tablet or pill form — it is a pre-filled injection pen that delivers semaglutide subcutaneously, meaning just beneath the skin. The phrase "Wegovy tablets" is one of the most common search terms used by people exploring this treatment, and it is important to clarify that distinction early so that patients have accurate expectations. The injectable format is what allows the drug to work reliably, as oral semaglutide behaves differently in the body and is currently only licensed for type 2 diabetes management under the brand name Rybelsus.

Semaglutide, the active ingredient in Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a natural hormone your gut releases after eating. It signals to your brain that you are full, slows the rate at which your stomach empties, and reduces the urge to eat between meals. Wegovy mimics this hormone at a much higher concentration than your body naturally produces, which is why it produces such a powerful suppression of appetite. In people taking Wegovy, the brain receives consistent "I am full" signals even when food intake has been reduced significantly.

The SCALE and STEP clinical trial programmes have demonstrated that semaglutide at the 2.4mg weekly dose produces an average weight loss of approximately 14.9% of body weight over 68 weeks when combined with a reduced-calorie diet and physical activity. For someone weighing 100kg, that represents nearly 15kg of weight loss — a clinically meaningful reduction that dramatically lowers the risk of type 2 diabetes, cardiovascular disease, hypertension, and joint problems.

• Wegovy contains semaglutide 2.4mg, a GLP-1 receptor agonist
• It mimics a natural gut hormone to reduce hunger and slow gastric emptying
• It is administered as a once-weekly subcutaneous injection, not an oral medicine
• Clinical evidence supports an average 15% reduction in body weight over 68 weeks
• It is manufactured by Novo Nordisk and is MHRA-approved in the UK

Who Can Use Wegovy for Weight Loss in the UK?

Wegovy is not a treatment for everyone who wants to lose a few pounds. It is a prescription-only medicine specifically licensed for adults with clinically significant obesity or overweight with associated health risks. Understanding whether you qualify is one of the most important steps before starting any form of semaglutide-based therapy, and in the UK, all prescriptions must be issued by a registered healthcare professional who has reviewed your individual health history.

To be eligible for Wegovy, you must meet one of the following clinical criteria as defined by the MHRA and NICE guidelines. Your body mass index (BMI) must be 30 kg/m² or above, which is classified as obese. Alternatively, if your BMI is between 27 and 29.9 kg/m², you may still qualify if you have at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnoea, or cardiovascular disease. The rationale behind these criteria is that these groups carry the greatest medical risk from excess weight and stand to benefit most from pharmacological intervention.

There are also a number of people for whom Wegovy is not appropriate. It should not be used during pregnancy or breastfeeding. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). People with a history of pancreatitis or severe gastrointestinal disease should also approach this treatment with caution. A thorough medical consultation will help identify whether Wegovy is right for you or whether an alternative such as Mounjaro weight loss injections (tirzepatide) may be more suitable for your situation.

• Eligible if BMI is 30 or above
• Eligible if BMI is 27–29.9 with a weight-related health condition
• Not suitable during pregnancy, breastfeeding, or if planning to become pregnant
• Contraindicated in people with personal or family history of MTC or MEN 2
• Must be prescribed by a registered healthcare professional following a full assessment

Wegovy Dose Escalation: Understanding the Treatment Schedule

One of the most important things to understand about Wegovy is that you do not start at the full therapeutic dose. The treatment uses a carefully structured escalation schedule designed to allow your body time to adjust to semaglutide and, crucially, to minimise the gastrointestinal side effects that many people experience when starting GLP-1 medications. Rushing the escalation is one of the most common reasons people experience severe nausea or discontinue treatment prematurely, so following the schedule as prescribed is essential.

The dose begins at 0.25mg once weekly for the first four weeks. This is a sub-therapeutic starting dose — it is not intended to produce significant weight loss at this stage but rather to acclimatise your digestive system to semaglutide. From week five, the dose increases to 0.5mg once weekly for another four weeks, then to 1mg, and then to 1.7mg, before finally reaching the full maintenance dose of 2.4mg weekly from week seventeen onwards. Each four-week period allows the body to stabilise before the next increment.

Many prescribers will advise that if you experience troublesome side effects at any stage, you can remain at the current dose for an extra four weeks before escalating. This flexibility is built into the treatment protocol and does not reduce the overall effectiveness of the medicine. The goal is to reach and sustain the 2.4mg maintenance dose, but getting there comfortably is just as important as the destination. You might also consider exploring Orlos (Orlistat) 60mg weight loss capsules as a complementary over-the-counter option under guidance during the early stages, though this should always be discussed with your prescriber first.

Week	Dose	Purpose	Expected Effects
Weeks 1–4	0.25mg once weekly	Initiation and tolerance	Body begins adjusting; minimal weight loss expected
Weeks 5–8	0.5mg once weekly	Gradual escalation	Mild appetite reduction begins; some nausea possible
Weeks 9–12	1mg once weekly	Continued escalation	Noticeable appetite suppression and early weight loss
Weeks 13–16	1.7mg once weekly	Near-maintenance dose	Significant appetite reduction and continued weight loss
Week 17 onwards	2.4mg once weekly	Full maintenance dose	Maximum therapeutic effect; sustained weight loss

Common Side Effects of Wegovy and How to Manage Them

Understanding the side effect profile of Wegovy before you start treatment is one of the most effective ways to prepare yourself for a successful experience. The majority of side effects are gastrointestinal in nature, occur during the dose escalation phase, and improve significantly once the body has adapted. Knowing this in advance means you are far less likely to panic or discontinue treatment unnecessarily at a stage when the medicine is just beginning to work.

The most frequently reported side effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These are all dose-dependent, meaning they tend to be worse when the dose increases and settle down within a few days to a couple of weeks. Eating smaller, lower-fat meals and avoiding lying down immediately after eating can significantly reduce nausea. Staying well hydrated is particularly important if vomiting or diarrhoea occurs, as dehydration can compound feelings of fatigue and dizziness. If you experience persistent heartburn or indigestion alongside Wegovy, it is worth checking in with your pharmacist and considering whether a short-term acid relief option such as Perrigo Heartburn & Acid Reflux 20mg Capsules could provide temporary relief.

Less common but more serious side effects include pancreatitis, which presents as severe, persistent abdominal pain that radiates to the back. This requires urgent medical attention and immediate discontinuation of Wegovy. Gallbladder problems, including gallstones and cholecystitis, have also been reported in some patients, thought to be related to rapid weight loss rather than the medication itself. There is also a theoretical risk of thyroid C-cell tumours based on rodent studies, though this has not been confirmed in human trials. Nevertheless, this is why Wegovy remains contraindicated in people with a history of or genetic predisposition to thyroid cancer.

• Nausea is the most common side effect, particularly during dose increases
• Eating smaller, blander meals and staying hydrated helps manage GI symptoms
• Severe or persistent abdominal pain could indicate pancreatitis — seek immediate help
• Gallbladder issues may occur, particularly during periods of rapid weight loss
• Most side effects are temporary and resolve within the first few weeks at each new dose

Wegovy Versus Other Weight Loss Treatments Available in the UK

With an expanding range of prescription and over-the-counter weight loss treatments available in the UK market in 2026, it can be genuinely confusing to know which option is best suited to your needs. Understanding how Wegovy compares to its closest alternatives — both in terms of mechanism of action and clinical evidence — helps you and your prescriber make a fully informed decision rather than simply choosing the most advertised product.

Tirzepatide, sold as Mounjaro, is arguably Wegovy's most significant competitor in the UK market. Unlike semaglutide, tirzepatide acts on both GLP-1 and GIP receptors, which appears to produce even greater average weight loss — approximately 20–22% in some trial arms at the highest dose. For people who have not responded adequately to Wegovy or who have a very high starting BMI, Mounjaro may offer superior results. However, access, cost, and individual tolerability still play a significant role in prescribing decisions. You can explore Mounjaro weight loss injections (tirzepatide) KwikPen as part of a full medical assessment.

Orlistat, available as the prescription-strength Xenical or the over-the-counter version Alli, works by blocking approximately 30% of dietary fat absorption in the gut. It produces more modest weight loss than semaglutide — typically 5–7% of body weight — and its gastrointestinal side effects, including oily stools and urgent bowel movements, can be socially uncomfortable. It remains useful for people who are not eligible for injectable GLP-1 medications or who prefer an oral option. Over-the-counter supplements such as XLS Medical Weight Loss Plus tablets provide a non-prescription alternative for those seeking additional support alongside lifestyle changes, though their evidence base is less robust than that of licensed prescription medicines.

• Mounjaro (tirzepatide) acts on both GLP-1 and GIP receptors and may produce greater weight loss than Wegovy
• Orlistat blocks fat absorption and produces modest weight loss with GI side effects
• Over-the-counter supplements support lifestyle changes but lack the clinical evidence of prescription medicines
• The best treatment depends on your BMI, health history, medication tolerability, and personal preference
• All prescription weight loss medicines require a qualified prescriber's assessment before starting

How to Get Wegovy Safely Through a UK Online Pharmacy

One of the biggest challenges facing people who want to access Wegovy in the UK is navigating availability, cost, and safety. NHS prescriptions for Wegovy are currently limited and being rolled out gradually through specialist weight management services and pilot programmes. For many people, private prescription services via regulated online pharmacies remain the most practical and accessible route to starting treatment in 2026. The key is ensuring any service you use is registered with the General Pharmaceutical Council (GPhC) and employs prescribers registered with the General Medical Council (GMC) or the GPhC itself.

When using an online pharmacy for Wegovy, the process should always begin with a comprehensive medical assessment. This typically involves an online consultation covering your weight, height, BMI, medical history, current medications, and any contraindications. A prescriber reviews your responses and, if appropriate, issues a private prescription. The medication is then dispensed by the pharmacy and delivered directly to your door in discreet, temperature-controlled packaging, as Wegovy requires refrigeration between 2°C and 8°C.

It is critical to avoid purchasing semaglutide products from unregulated sources, social media, or websites that do not require a prescription. Counterfeit semaglutide products have been seized in the UK and several European countries. These products carry no guarantee of sterility, correct dosage, or authentic ingredients and pose a genuine risk of serious harm. Stick exclusively to pharmacies displaying their GPhC registration number prominently and offering a verifiable prescribing process. You can also explore other supportive products through reputable channels — for example, XLS Medical Direct Fat Binder sachets are available without prescription and may complement your wider weight management plan.

• NHS access to Wegovy is available through specialist weight management services but remains limited
• GPhC-registered online pharmacies offer private prescriptions following a thorough online assessment
• Wegovy must be stored in a refrigerator between 2°C and 8°C — check delivery protocols carefully
• Never purchase semaglutide without a valid prescription or from unverified online sellers
• Always verify the GPhC registration number of any pharmacy before making a purchase

Key Takeaways

• Wegovy contains semaglutide 2.4mg and is a once-weekly injection — not an oral tablet — that mimics the GLP-1 hormone to suppress appetite and promote weight loss
• It is clinically proven to produce an average body weight reduction of approximately 15% over 68 weeks, making it one of the most effective pharmacological weight loss treatments currently available in the UK
• Eligibility requires a BMI of 30 or above, or 27 and above with a weight-related health condition, and must be prescribed following a full medical assessment
• Side effects are predominantly gastrointestinal, most pronounced during dose escalation, and can be minimised by eating smaller meals, staying hydrated, and following the gradual dose schedule carefully
• Safe access is available through GPhC-registered online pharmacies and select NHS weight management services — never purchase semaglutide from unverified sources

When to Seek Professional Advice

There are several situations where you should speak to a pharmacist, GP, or prescriber before starting or continuing Wegovy. If you experience severe abdominal pain that does not resolve, particularly pain radiating to your back, stop your injection immediately and contact a healthcare professional or call 111. This may indicate pancreatitis, which is a serious and potentially life-threatening condition. Similarly, if you develop persistent vomiting to the point where you cannot keep any fluids down, you should seek prompt medical review to prevent dehydration.

If you are taking oral contraceptives, you should be aware that semaglutide slows gastric emptying, which can theoretically reduce the absorption of oral medications taken around the same time. Your prescriber may recommend switching to a non-oral contraceptive method for at least four weeks after each dose increase. Anyone with thyroid symptoms — such as a lump in the neck, difficulty swallowing, or persistent hoarseness — should stop Wegovy and seek medical review promptly.

You should also contact your prescriber if you notice significant changes to your mood, experience symptoms of depression, or have any thoughts of self-harm. While a direct causal link has not been established, the MHRA and the European Medicines Agency have both highlighted this as an area requiring further monitoring. Open communication with your prescriber throughout your treatment journey is not just good practice — it is essential for safe, effective weight management.

Frequently Asked Questions

How long does it take for Wegovy tablets to start working?

Wegovy tablets typically begin to show appetite-suppressing effects within the first one to two weeks of starting treatment, though meaningful weight loss is usually noticed after four to eight weeks. Most clinical trials measured significant results over a 68-week period, with the greatest changes seen after reaching the full maintenance dose.

Is Wegovy safe to use alongside other medications?

Wegovy is generally considered safe for most adults, but it can interact with certain medicines, particularly oral contraceptives and diabetes drugs. You should always disclose your full medication list to your prescriber before starting, as semaglutide may slow gastric emptying and affect how other medicines are absorbed into your body.

What is the dose of Wegovy tablets and how does it increase?

The dose of Wegovy tablets starts at 0.25mg once weekly for four weeks and increases gradually every four weeks through 0.5mg, 1mg, and 1.7mg until reaching the full maintenance dose of 2.4mg once weekly. This slow escalation is specifically designed to reduce the risk of gastrointestinal side effects like nausea and vomiting.

Can you take Wegovy tablets if you have type 2 diabetes?

Wegovy can be prescribed to people with type 2 diabetes, though the lower-dose version of semaglutide called Ozempic is more commonly used for blood sugar control. Your prescriber will review your individual health profile, current diabetes medications, and HbA1c levels before confirming whether Wegovy is the most appropriate treatment for you.

Scientific References

1. NICE Technology Appraisal TA875 — Semaglutide for managing overweight and obesity (2023). National Institute for Health and Care Excellence.
2. MHRA — Wegovy (Semaglutide) Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency, UK.
3. Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The Lancet, 396(10264), 391–405. STEP 1 Trial.